10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

[X]	QUARTERLY REPORT UNDER TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2016
	OR
[   ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number   000-54745

LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP

(Exact name of registrant as specified in its charter)

Nevada

(State of incorporation)f

28202 N 58th St

Cave Creek, AZ 85331

(Address of principal executive offices)

(480) 275-2294

(Registrant's telephone number)

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days.   YES [X]     NO [   ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (SS 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   YES [   ]     NO [X]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of "large accelerated filer, "accelerated filer," "non-accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer	[   ]	Accelerated Filer	[   ]
Non-accelerated Filer (Do not check if smaller reporting company)	[   ]	Smaller Reporting Company	[X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   YES [ X ]     NO [  ]

As of November 17, 2016 there were 82,775,500 shares of the registrant's $0.00001 par value common stock issued and outstanding.

1

TABLE OF CONTENTS

		Page
PART I.  FINANCIAL INFORMATION
ITEM 1.	FINANCIAL STATEMENTS.	3
	Condensed Balance Sheets- Unaudited	3
	Condensed Statements of Operations- Unaudited	4
	Condensed Statements of Cash Flows- Unaudited	5
	Notes to the Financial Statements- Unaudited	6
ITEM 2.	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION.	8
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.	9
ITEM 4.	CONTROLS AND PROCEDURES.	9
ITEM 5.            OTHER INFORMATION		10
PART II.  OTHER INFORMATION
ITEM 1A.	RISK FACTORS.	11
ITEM 6.	EXHIBITS.	11
Signatures		12

2

LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP.
Condensed Balance Sheet
(Unaudited)
		Sept 30	Mar 31
		2016	2016
ASSETS
Current Assets
	Cash and cash equivalents	$ 1	$ 5
	Total current assets	1	5
	Property and equipment, net	4,912	5,458
TOTAL ASSETS		4,913	5,463
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities
	Accounts payable and accrued liabilities	9,894	15,313
	Due to related parties	60,948	51,458
	Total current liabilities	70,842	66,771
TOTAL LIABILITIES		70,842	66,771
Stockholder's equity (Deficit)
	Share capital
	Authorized:
	100,000,000 preferred shares, par value $0.00001
	300,000,000 common shares, par value $0.00001
	Issued and outstanding:
	Nil preferred shares
	81,275,000 common shares	828	828
	Additional paid-in capital	867,263	867,263
	Accumulated deficit	(934,020)	(929,399)
	Total stockholders' equity (deficit)	(65,929)	(61,308)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		$ 4,913	$ 5,463

The accompanying notes are an integral part of these unaudited financial statements

3

LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP.
Condensed Statement of Operations
(Unaudited)
		Six Months	Six Months	Three Months	Three Months
		Ended	Ended	Ended	Ended
		Sept 30	Sept 30	Sept 30	Sept 30
		2016	2015	2016	2015
Expenses
	Accounting and legal	$ 3,612	$ 5,426	$ 3,111	$ 4,019
	Amortization	546	-	-	-
	Filing and registration	20	-	-	-
	Stock transfer management	443	745	-	-
Net loss		$ (4,621)	$ (6,171)	$ (3,111)	$ (4,019)
Basic and diluted loss per share		$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
Weighted average number of common shares outstanding
	Basic and diluted	82,775,000	181,275,000	82,775,000	181,275,000

The accompanying notes are an integral part of these unaudited financial statements

4

LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP.
Condensed Statement of Cash Flows
(Unaudited)
		Six Months	Six Months
		Ended	Ended
		Sept 30	Sept 30
		2016	2015
Cash flows from operating activities
	Net income (Loss)	$ (4,621)	$ (6,171)
	Changes in non-cash working capital
	Accounts payable and accrued liabilities	(5,419)	526
	Amortization	546	-
	Net cash provided by (used in) operating activities	(9,494)	(5,645)
Cash flows from investing activities
	Purchase of equipment	-	(6,550)
	Net cash provided by (used in) financing activities	-	(6,550)
Cash flows from financing activities
	Due to related parties	9,490	10,691
	Net cash provided by (used in) financing activities	9,490	10,691
Increase (Decrease) in cash and cash equivalents		(4)	(1,504)
Cash and cash equivalents, beginning of period		5	1,505
Cash and cash equivalents, end of period		$ 1	$ 1
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for interest		$ -	$ -
Cash paid for income taxes		-	-
Total cash paid for interest and income taxes		$ -	$ -

The accompanying notes are an integral part of these unaudited financial statements.

5

LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP

Notes to the Financial Statements

(Unaudited)

1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Lotus Bio-Technology Development Corp (“we”, “our”, the “Company”) was formed on March 24, 2011 with planned principal operations as an independent motion picture producer.  In 2016, the Company has shifted its focus and began exploring opportunities in the organic growth and farming sector in China.

In May of 2016, the Company has changed its name, president and business direction and entered into the organic bio development space.

On May 7, 2016, The Company also signed a marketing and distribution agreement with Hunan Canshi in China. Lotus Bio-Technology will provide Marketing, Sales and distribution for organic related products produced exclusively by Hunan Canshi. The term of the agreement is 10 years.  General terms of the agreement state that Lotus will provide; Marketing, sales and distribution for Hunan Canshi and Hunan Canshi will provide a variety of Organic related products, Both Hunan Canshi and Lotus Bio-Technology intend to collaborate on a variety of business related issues such as promotion of products through social media and corporate website, development of joint marketing materials and training and support for all staff. The agreement also states that subsidiary company is to be created of which Lotus will own 51% in the newly established Hong Kong Entity As of today that process has not completed.

The accompanying unaudited interim financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information required to be included in a complete set of financial statements in accordance with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the six months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2017. The accompanying unaudited financial statements should be read in conjunction with the financial statements and related notes included in the Company's March 31, 2016 Form 10-K.

2. GOING CONCERN

The Company’s interim unaudited financial statements are prepared using generally accepted accounting principles applicable to a going concern which contemplates realization of assets and liquidation of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has incurred net loss of $4,621 for the six months ended September 30, 2016. The Company has not generated any operating revenues to date, has a working capital deficit and existence is dependent upon management’s ability to develop profitable operations. These conditions raise substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments that might result from this uncertainty.

Our activities to date have been supported by equity financing and demand loans from our major shareholder. Management continues to seek funding from its shareholders and other qualified investors to pursue its business plan and new course of action.

6

3. DUE TO RELATED PARTY

As at September 30, 2016 the balance due to a majority shareholder was $51,754 .The amount due to the  major shareholder is unsecured, non-interest bearing and due on demand.

As at September 30, 2016 the balance due to other related third parties was $9,194.

4. SUBSEQUENT EVENTS

As at September 30, 2016, there is no subsequent events.

7

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION.

Forward-Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

 Management’s Discussion and Analysis of Financial Condition and Results of Operations

Lotus Bio-Technology Development Corp was formed under the laws of the State of Nevada.  We have not commenced our planned principal operations.

Plan of Operation

All of the information following is based upon estimates.  We are a startup company, or in other words, a company with a limited operating history, since our operations have been limited to incorporating Lotus Bio-Technology Development Corp; issuing stock to Zoltan Nagy, our previous officer and director; developing our business plan; began developing our website; Since then we have spent all of the money raised in our public offering.

Lotus Bio-Technology is actively seeking new opportunities in the emerging bio-natural industry in China.  Our mandate is to partner with companies that are in the organic growth sector that meet the criteria we have set out in order to grow various plant products under strict organic standards. Products that can be refined into various consumer products which are completely natural and strike a balance between affordability while being produced from an environmentally responsible manner. Products that are void of pesticides, synthetic fertilizers, anti-biotics, growth hormones and any other dangerous chemicals.

In anticipation of the Company's growth strategy, Lotus Bio-Technology intends to establish a corporate office in Yong Zhou City to serve as our China headquarters for its daily business activity. Our local office is currently in Cave Creek Arizona.

Limited operating history; need for additional capital

There is no historical financial information about us upon which to base an evaluation of our performance. We are in a start-up stage operations and have not generated any revenues. We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources and possible cost overruns due to price and cost increases in services and products. To become profitable and competitive, we have to sell our products, and execute our business plan. We are not seeking equity financing at the present time.

8

We have no assurance that future financing will be available to us on acceptable terms.  If financing is not available on satisfactory terms, we may be unable to continue operations.  Equity financing could result in additional dilution to existing shareholders.

Results of operations

Results of operations for the three and six months ended September 30, 2016 and September 30, 2015

We have not earned any revenues during the three and six months ended September 30, 2016. We incurred expenses and a net loss in the amount of $3,111 for the three months ended September 30, 2016. Our expenses during the three months ended September 30, 2016 consisted of accounting and legal fees of $3,111. By comparison, we incurred a net loss of $4,019 for the three months ended September 30, 2015. We incurred expenses and a net loss in the amount of $4,621 for the six months ended September 30, 2016. Our expenses during the six months ended September 30, 2016 consisted of accounting and legal fees of $5,426, general and administrative fees of $20, stock transfer management fee of $745, and amortization expense of $546. By comparison, we incurred a net loss of $6,171 for the six months ended September 30, 2015.

Our losses are attributable to operating expenses together with a lack of any revenues.

Liquidity and capital resources

As of the date of this report, we have yet to generate any revenues from our business operations.

As of September 30, 2016, our total current assets were $1 and our total current liabilities were $70,842. Accordingly, we had a working capital deficit of $70,841 as of September 30, 2016.

During the six months ended September 30, 2016, the former sole officer and director of the Company paid no expenses on behalf of the Company. As of September 30, 2016, $60,948 was due to the previous sole officer and director. The amount due was unsecured, non-interest bearingand due on demand.

Going Concern

As discussed in the notes to our financial statements, we have not established a source of revenue. This has raised substantial doubt to our auditors about our ability to continue as a going concern. Without realization of additional capital, it would be unlikely for us to continue as a going concern.

Our activities to date have been supported by equity financing and demand loans from our major shareholder. Management continues to seek funding from its shareholders and other qualified investors to pursue its business plan and new course of action.

Off Balance Sheet Arrangements

As of September 30, 2016, there were no off balance sheet arrangements.

ITEM 3.                    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

9

ITEM 4.                    CONTROLS AND PROCEDURES.

Under the supervision and with the participation of our management, including the Principal Executive Officer and Principal Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures as required by Exchange Act Rule 13a-15(b) as of September 30, 2016.  Based on that

evaluation, the Principal Executive Officer and Principal Financial Officer have concluded that these disclosure controls and procedures are not effective.

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2016, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 5.               OTHER INFORMATION

On May 7^th, 2016, The Company also signed a marketing and distribution agreement with Hunan Canshi in China. Lotus Bio-Technology will provide Marketing, Sales and distribution for organic related products produced exclusively by Hunan Canshi. The agreement is 10 years.  General terms of the agreement state that Lotus will provide; Marketing, sales and distribution for Hunan Canshi and Hunan Canshi will provide a variety of Organic related products, Both Hunan Canshi and Lotus Bio-Technology intend to collaborate on a variety of business related issues such as promotion of products through social media and corporate website, development of joint marketing materials and training and support for all staff. The agreement also states that subsidiary company is to be created of which Lotus will own 51% in a newly established Hong Kong entity. As of today that process has not completed.

10

PART II - OTHER INFORMATION

ITEM 1A.               RISK FACTORS.

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 6.                    EXHIBITS.

		Incorporated by reference			Filed
Exhibit	Document Description	Form	Date	Number	herewith
3.1	Articles of Incorporation.	S-1	6/10/11	3.1
3.2	Bylaws.	S-1	6/10/11	3.2
14.1	Code of Ethics.	10-K	6/22/12	14.1
31.1	Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.				X
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.				X
99.2	Audit Committee Charter.	10-K	6/22/12	99.2
99.3	Disclosure Committee Charter.	10-K	6/22/12	99.3
101.INS	XBRL Instance Document.
101.SCH	XBRL Taxonomy Extension – Schema.
101.CAL	XBRL Taxonomy Extension – Calculations.
101.DEF	XBRL Taxonomy Extension – Definitions.
101.LAB	XBRL Taxonomy Extension – Labels.
101.PRE	XBRL Taxonomy Extension – Presentation.

11

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on this 21^ST day of November, 2016.

LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP
BY:	Michael Palethorpe
	Michael Palethorpe
	President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Secretary, Treasurer and sole member of the Board of Directors

12

EX-31.1

Exhibit 31.1

SARBANES-OXLEY SECTION 302(a) CERTIFICATION

               I, Michael Palethorpe, certify that:

1.	I have reviewed this Form 10-Q for the period ended September 30, 2016 of Lotus Bio-Technology Development Corp;
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.	I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and,

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.	I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date:	November 21, 2016	/s/ Michael Palethorpe
		Michael Palethorpe
		Principal Executive Officer and Principal Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. Section 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Lotus Bio-Technology Development Corp. (the “Company”) on Form 10-Q for the period ended September 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the “report”), I, Michael Palethorpe, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)	The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated this 21^st day of November, 2016.

/s/ Michael Palethorpe

Michael Palethorpe

Chief Executive Officer and Chief Financial Officer

XML

Document and Entity Information	6 Months Ended
	Sep. 30, 2016 shares
Document and Entity Information:
Entity Registrant Name	Lotus Biotech Development Corp.
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Entity Central Index Key	0001520592
Current Fiscal Year End Date	--03-31
Entity Common Stock, Shares Outstanding	81,275,000
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	No
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q2
Trading Symbol	lbtd

XML

LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP. - Balance Sheets - USD ($)		Sep. 30, 2016	Mar. 31, 2016
Current Assets:
Cash and cash equivalents		$ 1	$ 5
Total Current Assets		1	5
Property and equipment, net		4,912	5,458
TOTAL ASSETS		4,913	5,463
Current liabilities:
Accounts payable and accrued liabilities		9,894	15,313
Due to related parties		60,948	51,458
Total Current Liabilities		70,842	66,771
TOTAL LIABILITIES		70,842	66,771
Stockholders' equity (Deficit)
Preferred stock	[1]
Common stock	[2]	828	828
Additional paid-in capital		867,263	867,263
Accumulated deficit		(934,020)	(929,399)
TOTAL STOCKHOLDERS' EQUITY (DEFICIT)		(65,929)	(61,308)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)		$ 4,913	$ 5,463

[1] 100,000,000 authorized, par value $0.00001, nil issued and outstanding.

[2] 300,000,000 authorized, par value $0.00001, 81,275,000 issued and outstanding.

XML

LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP. - Balance Sheets, Parenthetical - $ / shares	Sep. 30, 2016	Mar. 31, 2016
Statement of Financial Position
Common Stock, Par Value	$ 0.00001	$ 0.00001
Common Stock, Shares Authorized	300,000,000	300,000,000
Common Stock, Shares Issued	81,275,000	82,775,000
Common Stock, Shares Outstanding	81,275,000	82,775,000
Preferred Stock, Par Value	$ 0.00001	$ 0.00001
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued
Preferred Stock, Shares Outstanding

XML

LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP. - Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Expenses
Accounting and legal	$ 3,111	$ 4,019	$ 3,612	$ 5,426
Amortization			546
Filing and registration			20
Stock transfer management			443	745
Net loss	$ (3,111)	$ (4,019)	$ (4,621)	$ (6,171)
Basic and diluted loss per common share	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
Weighted average number of common shares outstanding, basic and diluted	82,775,000	181,275,000	82,775,000	181,275,000

XML

LOTUS BIO-TECHNOLOGY DEVELOPMENT CORP. - Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (3,111)	$ (4,019)	$ (4,621)	$ (6,171)
Changes in operating assets and liabilities
Accounts payable and accrued liabilities, increase decrease			(5,419)	526
Amortization			546
Net cash provided by (used in) operating activities			(9,494)	(5,645)
Cash flows from investing activities
Purchase of equipment				(6,550)
Net cash provided by (used in) investing activities				(6,550)
Cash flows from financing activities
Due to related parties			9,490	10,691
Net cash provided by (used in) financing activities			9,490	10,691
Increase decrease in cash and cash equivalents			(4)	(1,504)
Cash and cash equivalents, beginning of period			5	1,505
Cash and cash equivalents, end of period	$ 1	$ 1	1	1
Supplemental Cash Flow Information
Cash paid for interest
Cash paid for income taxes

XML

1. Description of Business and Basis of Presentation

6 Months Ended

Sep. 30, 2016

Notes

1. Description of Business and Basis of Presentation

1. DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

Lotus Bio-Technology Development Corp (“we”, “our”, the “Company”) was formed on March 24, 2011 with planned principal operations as an independent motion picture producer.  In 2016, the Company has shifted its focus and began exploring opportunities in the organic growth and farming sector in China.

In May of 2016, the Company has changed its name, president and business direction and entered into the organic bio development space.

On May 7, 2016, The Company also signed a marketing and distribution agreement with Hunan Canshi in China. Lotus Bio-Technology will provide Marketing, Sales and distribution for organic related products produced exclusively by Hunan Canshi. The term of the agreement is 10 years.  General terms of the agreement state that Lotus will provide; Marketing, sales and distribution for Hunan Canshi and Hunan Canshi will provide a variety of Organic related products, Both Hunan Canshi and Lotus Bio-Technology intend to collaborate on a variety of business related issues such as promotion of products through social media and corporate website, development of joint marketing materials and training and support for all staff. The agreement also states that subsidiary company is to be created of which Lotus will own 51% in the newly established Hong Kong Entity As of today that process has not completed.

The accompanying unaudited interim financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information required to be included in a complete set of financial statements in accordance with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the six months ended September 30, 2016 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2017. The accompanying unaudited financial statements should be read in conjunction with the financial statements and related notes included in the Company's March 31, 2016 Form 10-K.

XML

2. Going Concern

6 Months Ended

Sep. 30, 2016

Notes

2. Going Concern

2. GOING CONCERN

The Company’s interim unaudited financial statements are prepared using generally accepted accounting principles applicable to a going concern which contemplates realization of assets and liquidation of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has incurred net loss of $4,621 for the six months ended September 30, 2016. The Company has not generated any operating revenues to date, has a working capital deficit and existence is dependent upon management’s ability to develop profitable operations. These conditions raise substantial doubt that the Company will be able to continue as a going concern. These financial statements do not include any adjustments that might result from this uncertainty.

Our activities to date have been supported by equity financing and demand loans from our major shareholder. Management continues to seek funding from its shareholders and other qualified investors to pursue its business plan and new course of action.

XML

3. Due To Related Party

6 Months Ended

Sep. 30, 2016

Notes

3. Due To Related Party

3. DUE TO RELATED PARTY

As at September 30, 2016 the balance due to a majority shareholder was $51,754 .The amount due to the  major shareholder is unsecured, non-interest bearing and due on demand.

As at September 30, 2016 the balance due to other related third parties was $9,194.

XML

4. Subsequent Events

6 Months Ended

Sep. 30, 2016

Notes

4. Subsequent Events

4. SUBSEQUENT EVENTS

As at September 30, 2016, there is no subsequent events.

XML

3. Due To Related Party (Details)	Sep. 30, 2016 USD ($)
Details
Due to Officers or Stockholders, Current	$ 51,754
Due to Other Related Parties	$ 9,194